Aligning incentives to guide
strategic capital for social good
What we do
Identify key knowledge gaps and effective solutions
Design and implement research programs
Evaluate funding opportunities and guide strategic use of private capital
Provide expert counsel on science policy issues
Well-informed capital can fuel breakthroughs and catalyze social impact.
Our values
Meaningful
relationships
The best work happens when sectors weave their expertise together to address a common goal
Transparency
& collaboration
Free sharing of data, insights, resources and best practices are foundational to advance solutions efficiently
Openness
& flexibility
Science is dynamic and our work is too — we must be adaptive and responsive to meet the moment
Our impact
Generating impact is at the core of our approach. Here is a selection of recent milestones. For more information or to partner, please connect with us.
Launched the Collaborative Research Network (CRN) an international, multidisciplinary, and multi-institutional network of over 130 collaborating investigators working to address high-priority basic science questions in Parkinson’s. Learn more
Launched Global Parkinson's Genetics Program (GP2) to genotype >150,000 volunteers around the world to further understand the genetic architecture of Parkinson’s disease and make that information globally relevant. Learn more
Supported the expansion of Parkinson’s Progression Markers Initiative (PPMI), growing its clinical cohort to more than 4,000 participants at 50+ sites, with half of the study population carrying clinical or genetic risk factors without manifesting Parkinson’s. Learn more
Supported the expansion of iPSC Neurodegenerative Initiative (iNDI) to include up to 20 human isogenic iPSC lines expressing Parkinson’s disease-associated mutations of interest and creating isogenic controls for genetic Parkinson’s disease patient-derived iPSC lines from PPMI. Learn more
Piloted the development of standardized methodologies for using wastewater-based epidemiology for assessing SARS-CoV-2 and other viral pathogens across 8 cities in northern California. Learn more
Expanded SCAN model into the Central Valley through the launch of Healthy Central Valley Together. Learn more
Initiating a nationwide pilot using the SCAN approach through WastewaterScan powered by Verily. Learn more
Partnered with the Milken Institute for Strategic Philanthropy to launch BD² in September 2022, the largest private investment focused on the study of bipolar disorder. Learn more